Experimental drug reverses severe fatty liver disease by repairing the gut
Researchers at the University of Michigan have developed an experimental drug called DT-109 that reverses severe fatty liver disease in animal models. The drug works by repairing the gut barrier and preventing harmful bacterial products from triggering liver inflammation.
Why it matters
This discovery offers a potential new therapeutic pathway for MASH, a serious liver condition that currently lacks effective treatment options.
An experimental drug developed at Michigan Medicine has shown the ability to reverse severe fatty liver disease in animal studies by restoring gut health. The findings, published in The Journal of Clinical Investigation , suggest that targeting the connection between the gut and liver could offer a promising new approach for treating metabolic dysfunction-associated steatohepatitis (MASH).
The article reports on scientific findings from a university study without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in